A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC

被引：0
|
作者：
Ciuleanu, T-E. [1 ]
Joshi, R. [2 ]
Gryaznov, S. [3 ]
Vitoc, V. [3 ]
Obrocea, M. [3 ]
机构：
[1] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol, Cluj Napoca, Romania
[2] Canc Res SA, Med Oncol, Adelaide, SA, Australia
[3] MAIA Biotechnol Inc, Clin Dev, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1193TiP
引用
收藏
页码：S1094 / S1094
页数：1
相关论文
共 50 条
  • [21] A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
    Sanjay Goel
    Umang Swami
    Kirushna Kumar
    Christian Dittrich
    Larisa Reyderman
    Minish Jain
    Joseph Aisner
    James Song
    Daniel P. Petrylak
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 567 - 578
  • [22] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [23] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [24] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [25] A FIRST IN-HUMAN, MULTICENTER, OPEN-LABEL, DOSE-FINDING PHASE 1 STUDY OF THE IMMUNE STIMULATOR ANTIBODY CONJUGATE NJH395 IN PATIENTS WITH NONBREAST HER2+ADVANCED MALIGNANCIES
    Janku, Filip
    Han, Sae-Won
    Doi, Toshihiko
    Ajani, Jaffer
    Kuboki, Yasutoshi
    Mahling, Ping
    Subramanian, Kulandayan
    Pelletier, Marc
    Askoxylakis, Vasileios
    Siena, Salvatore
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A230 - A230
  • [26] A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes
    Marwaha, Ashish K.
    Chow, Samuel
    Pesenacker, Anne M.
    Cook, Laura
    Sun, Annika
    Long, S. Alice
    Yang, Jennie H. M.
    Ward-Hartstonge, Kirsten A.
    Williams, Evangelia
    Domingo-Vila, Clara
    Halani, Khalif
    Harris, Kristina M.
    Tree, Timothy I. M.
    Levings, Megan K.
    Elliott, Thomas
    Tan, Rusung
    Dutz, Jan P.
    IMMUNOTHERAPY ADVANCES, 2022, 2 (01):
  • [27] Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
    Erika P. Hamilton
    Gerald S. Falchook
    Judy S. Wang
    Siqing Fu
    Amit M. Oza
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Lone Ottesen
    Ganesh M. Mugundu
    Elza C. de Bruin
    Mark J. O’Connor
    Suzanne F. Jones
    David R. Spigel
    Bob T. Li
    Targeted Oncology, 2024, 19 (6) : 879 - 892
  • [28] AN OPEN-LABEL, DOSE-FINDING STUDY OF WY-45,030, A NOVEL BICYCLIC ANTIDEPRESSANT
    SCHWEIZER, E
    CLARY, C
    WEISE, C
    RICKELS, K
    PSYCHOPHARMACOLOGY BULLETIN, 1988, 24 (01) : 195 - 197
  • [29] A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
    Friedlander, Michael
    Hancock, Kenneth C.
    Rischin, Danny
    Messing, Mark J.
    Stringer, Claude A.
    Matthys, Gemma M.
    Ma, Bo
    Hodge, Jeffrey P.
    Lager, Joanne J.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (01) : 32 - 37
  • [30] Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma
    Abou-Alfa, Ghassan K.
    Mayer, Robert
    Venook, Alan P.
    O'Neill, Allison F.
    Beg, Muhammad S.
    LaQuaglia, Michael
    Kingham, Peter T.
    Kobos, Rachel
    Basturk, Olca
    Brennan, Cameron
    Yopp, Adam
    Harding, James J.
    Leong, Stephen
    Crown, John
    Hoti, Emir
    Leonard, Gregory
    Ly, Michele
    Bradley, Mikaela
    Valentino, Emily
    Markowitz, David
    Zukiwski, Alexander
    Ren, Ken
    Gordan, John D.
    ONCOLOGIST, 2020, 25 (12): : E1837 - E1845
12345